Publication date: Jun 07, 2019
Progressive multifocal leukoencephalopathy (PML) is a severe adverse event of natalizumab (NTZ). The administration of NTZ with extended interval dosing (EID) has been proposed as a strategy to potentially reduce the incidence of PML while maintaining its therapeutic efficacy.
In the current paper, we describe 4 cases of NTZ-PML in EID included in the Italian PML cohort.
The patients developed PML after at least 38 NTZ infusions. Their John Cunningham virus (JCv) index was > 1.5, and patients had not previously used immunosuppressant. Two patients were asymptomatic at PML onset, while two had mild motor impairment of the right hand and anomia, respectively. All of them had undetectable viral load but one (37 JCv copies/ml). In all patients, MRI revealed unilobar lesions with deferred contrast enhancement suggestive of immune reconstitution. The clinical course ended with a favorable clinical outcome (ΔEDSS up to 1).
Although PML in EID seems to occur less frequently than in conventional dosing regimen, strict monitoring of high-risk patients contributed to the indolent course observed in the four described cases, characterized by a prolonged pre-symptomatic phase, paucisymptomatic onset, low JCv load, less severe functional impairment during immune reconstitution, and a mild disability burden.
Scarpazza, C., De Rossi, N., Tabiadon, G., Turrini, M.V., Gerevini, S., and Capra, R. Four cases of natalizumab-related PML: a less severe course in extended interval dosing? 18278. 2019 Neurol Sci.
|disease||MESH||Progressive multifocal leukoencephalopathy|
- Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate.
- #AANAM – Biogen Offers Update on Development Plans for MS Therapies
- Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing.
- Clinical Challenges: PML in Multiple Sclerosis